Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 16/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451783 | 0.86 | CCR5 (0.54) | CCR5KCNH2NPC1L1 | |
| SCHEMBL7605901 | 0.83 | JAK2 (0.46) | JAK2JAK1CCR5NR1H2USP30 | |
| SCHEMBL5456416 | 0.77 | CCR5 (0.51) | CCR5KCNH2 | |
| SCHEMBL7544743 | 0.76 | CCR5 (0.54) | CCR5KCNH2 | |
| SCHEMBL7603913 | 0.75 | CCR5 (0.43) | CCR5KCNH2 | |
| SCHEMBL7608991 | 0.75 | CCR5 (0.62) | CCR5KCNH2 | |
| SCHEMBL7608985 | 0.75 | CCR5 (0.62) | CCR5KCNH2 | |
| SCHEMBL5452690 | 0.75 | THRB (0.51) | CCR5 | |
| SCHEMBL15803575 | 0.73 | NR1H2 (0.55) | JAK2JAK1NR1H2 | |
| SCHEMBL7604742 | 0.73 | CCR5 (0.42) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | JAK2 1989/4885JAK1 2188/4885CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.